Compare MRNA & EVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRNA | EVR |
|---|---|---|
| Founded | 2010 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 11.7B |
| IPO Year | 2018 | 2006 |
| Metric | MRNA | EVR |
|---|---|---|
| Price | $27.57 | $332.15 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 9 |
| Target Price | $33.91 | ★ $320.11 |
| AVG Volume (30 Days) | ★ 9.9M | 344.0K |
| Earning Date | 11-06-2025 | 10-29-2025 |
| Dividend Yield | N/A | ★ 1.01% |
| EPS Growth | N/A | ★ 61.11 |
| EPS | N/A | ★ 12.55 |
| Revenue | $2,232,000,000.00 | ★ $3,542,875,000.00 |
| Revenue This Year | N/A | $25.39 |
| Revenue Next Year | $0.77 | $16.43 |
| P/E Ratio | ★ N/A | $26.43 |
| Revenue Growth | N/A | ★ 27.03 |
| 52 Week Low | $22.28 | $148.63 |
| 52 Week High | $48.92 | $364.42 |
| Indicator | MRNA | EVR |
|---|---|---|
| Relative Strength Index (RSI) | 60.85 | 62.83 |
| Support Level | $23.92 | $310.93 |
| Resistance Level | $26.00 | $322.82 |
| Average True Range (ATR) | 1.29 | 11.11 |
| MACD | 0.32 | 3.21 |
| Stochastic Oscillator | 99.82 | 87.16 |
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Evercore is a leading independent investment banking advisory firm that generates most of its revenue through merger and acquisition and restructuring advisory services, with much smaller capital raising, equities trading, and investment management businesses. Founded in 1995, it has built a reputation for advising on some of the world's largest and most complex transactions. The firm operates globally with a strong presence in the US and Europe, serving corporations, financial sponsors, and government clients. Its business model emphasizes high-touch, conflict-free advice rather than balance sheet lending, allowing it to compete with larger bulge-bracket banks.